podcast
Summary
What Bret considers to be an attractive risk/reward scenario in biotech.
Why upcoming catalysts are the name of the game regarding small cap biotech.
The 5 companies Bret sees positive catalysts for in the 4th quarter.
How Bret would work companies like this into a portfolio (ex: position-sizing, etc).